EA038250B1 - Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление - Google Patents
Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление Download PDFInfo
- Publication number
- EA038250B1 EA038250B1 EA201791562A EA201791562A EA038250B1 EA 038250 B1 EA038250 B1 EA 038250B1 EA 201791562 A EA201791562 A EA 201791562A EA 201791562 A EA201791562 A EA 201791562A EA 038250 B1 EA038250 B1 EA 038250B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- fragment
- complex
- protease
- cytomegalovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152221.6A EP3048114A1 (en) | 2015-01-22 | 2015-01-22 | Cytomegalovirus antigens and uses thereof |
| PCT/IB2016/050335 WO2016116904A1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201791562A1 EA201791562A1 (ru) | 2018-04-30 |
| EA038250B1 true EA038250B1 (ru) | 2021-07-29 |
Family
ID=52434568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791562A EA038250B1 (ru) | 2015-01-22 | 2016-01-22 | Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10167321B2 (enExample) |
| EP (3) | EP3048114A1 (enExample) |
| JP (1) | JP6717836B2 (enExample) |
| KR (1) | KR20170100039A (enExample) |
| CN (1) | CN107531761B (enExample) |
| AU (2) | AU2016210548B2 (enExample) |
| BE (1) | BE1023087B1 (enExample) |
| BR (1) | BR112017015567A2 (enExample) |
| CA (1) | CA2974041C (enExample) |
| DK (1) | DK3247722T5 (enExample) |
| EA (1) | EA038250B1 (enExample) |
| ES (1) | ES2937959T3 (enExample) |
| FI (1) | FI3247722T3 (enExample) |
| HR (1) | HRP20230177T1 (enExample) |
| HU (1) | HUE061175T2 (enExample) |
| IL (1) | IL253366B (enExample) |
| LT (1) | LT3247722T (enExample) |
| MX (1) | MX382518B (enExample) |
| PL (1) | PL3247722T3 (enExample) |
| PT (1) | PT3247722T (enExample) |
| SG (1) | SG11201705740UA (enExample) |
| SI (1) | SI3247722T1 (enExample) |
| WO (1) | WO2016116904A1 (enExample) |
| ZA (1) | ZA201704912B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2772265T1 (en) * | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2955306C (en) | 2014-07-16 | 2021-06-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP7133468B2 (ja) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
| EP3423091A4 (en) | 2016-03-03 | 2019-10-30 | Duke University | COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| EP3519428A4 (en) | 2016-10-03 | 2020-07-08 | Duke University | METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS |
| TN2019000124A1 (en) | 2016-10-18 | 2020-10-05 | Univ Oregon Health & Science | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| EP3612550B1 (en) * | 2017-04-19 | 2025-06-18 | GlaxoSmithKline Biologicals S.A. | Modified cytomegalovirus proteins and stabilized complexes |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| WO2019070730A1 (en) | 2017-10-02 | 2019-04-11 | Duke University | MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES |
| AU2019228551B2 (en) | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| JP7614842B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性エプスタインバーウイルスポリペプチド |
| WO2020072169A1 (en) | 2018-10-01 | 2020-04-09 | Duke University | Hiv-1 envelope stabilizing mutations |
| MX2021004273A (es) * | 2018-10-17 | 2021-12-10 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| CN109627330A (zh) * | 2018-12-18 | 2019-04-16 | 马鞍山史记动物健康管理有限公司 | 一种猪伪狂犬病毒高效价阳性血清制备方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| US11857622B2 (en) * | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| CN118459574B (zh) * | 2022-10-21 | 2025-06-17 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014005959A1 (en) * | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU635844B2 (en) | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| EP3031469B1 (en) | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US8124093B2 (en) * | 2008-07-16 | 2012-02-28 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| EP3456316A1 (en) | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| SG11201501623PA (en) * | 2012-10-30 | 2015-05-28 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| AU2014369177B2 (en) | 2013-12-20 | 2017-04-20 | Novartis Ag | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
| EP3604331A1 (en) | 2013-12-20 | 2020-02-05 | Novartis AG | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
-
2015
- 2015-01-22 EP EP15152221.6A patent/EP3048114A1/en not_active Withdrawn
-
2016
- 2016-01-22 BR BR112017015567A patent/BR112017015567A2/pt not_active Application Discontinuation
- 2016-01-22 MX MX2017009538A patent/MX382518B/es unknown
- 2016-01-22 BE BE2016/5050A patent/BE1023087B1/fr not_active IP Right Cessation
- 2016-01-22 LT LTEPPCT/IB2016/050335T patent/LT3247722T/lt unknown
- 2016-01-22 DK DK16702210.2T patent/DK3247722T5/da active
- 2016-01-22 PL PL16702210.2T patent/PL3247722T3/pl unknown
- 2016-01-22 EP EP22203406.8A patent/EP4180056A1/en active Pending
- 2016-01-22 US US15/544,730 patent/US10167321B2/en active Active
- 2016-01-22 HR HRP20230177TT patent/HRP20230177T1/hr unknown
- 2016-01-22 SI SI201631665T patent/SI3247722T1/sl unknown
- 2016-01-22 HU HUE16702210A patent/HUE061175T2/hu unknown
- 2016-01-22 JP JP2017538387A patent/JP6717836B2/ja active Active
- 2016-01-22 FI FIEP16702210.2T patent/FI3247722T3/fi active
- 2016-01-22 EP EP16702210.2A patent/EP3247722B1/en active Active
- 2016-01-22 CN CN201680017610.XA patent/CN107531761B/zh active Active
- 2016-01-22 KR KR1020177023123A patent/KR20170100039A/ko not_active Ceased
- 2016-01-22 WO PCT/IB2016/050335 patent/WO2016116904A1/en not_active Ceased
- 2016-01-22 AU AU2016210548A patent/AU2016210548B2/en not_active Ceased
- 2016-01-22 CA CA2974041A patent/CA2974041C/en active Active
- 2016-01-22 PT PT167022102T patent/PT3247722T/pt unknown
- 2016-01-22 ES ES16702210T patent/ES2937959T3/es active Active
- 2016-01-22 SG SG11201705740UA patent/SG11201705740UA/en unknown
- 2016-01-22 EA EA201791562A patent/EA038250B1/ru unknown
-
2017
- 2017-07-09 IL IL253366A patent/IL253366B/en unknown
- 2017-07-19 ZA ZA2017/04912A patent/ZA201704912B/en unknown
-
2018
- 2018-09-10 AU AU2018226521A patent/AU2018226521B2/en not_active Ceased
- 2018-11-15 US US16/192,347 patent/US20190276498A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014005959A1 (en) * | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
Non-Patent Citations (3)
| Title |
|---|
| CLAUDIO CIFERRI, SUMANA CHANDRAMOULI, DANILO DONNARUMMA, PAVEL A. NIKITIN, MICHAEL A. CIANFROCCO, RACHEL GERREIN, ADAM L. FEIRE, S: "Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 6, 10 February 2015 (2015-02-10), pages 1767 - 1772, XP055201992, ISSN: 00278424, DOI: 10.1073/pnas.1424818112 * |
| RYCKMAN BRENT J ET AL: "Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.", JOURNAL OF VIROLOGY (ONLINE), AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 1, 1 January 2008 (2008-01-01), US, pages 60 - 70, XP002519851, ISSN: 1098-5514, DOI: 10.1128/JVI.01910-07 * |
| WEN YINGXIA; MONROE JAMES; LINTON CHRISTINE; ARCHER JACOB; BEARD CLAYTON W.; BARNETT SUSAN W.; PALLADINO GIUSEPPE; MASON PETER W.;: "Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 32, no. 30, 14 May 2014 (2014-05-14), AMSTERDAM, NL, pages 3796 - 3804, XP029006326, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2014.05.004 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018226521B2 (en) | Cytomegalovirus antigens and uses thereof | |
| EP3294329B1 (en) | Novel baculovirus vectors and methods of use | |
| CN111603557A (zh) | 一种包膜替换型病毒载体疫苗及其构建方法 | |
| DK2968493T3 (en) | Enhanced poxvirus vaccines. | |
| RS61456B1 (sr) | Stabilizovani rastvorljivi pre-fuzioni rsv f protein za primenu u profilaksi rsv infekcije | |
| US20230174588A1 (en) | A vaccine against sars-cov-2 and preparation thereof | |
| WO2015181142A1 (en) | Cytomegalovirus complexes and uses thereof | |
| JP2025523631A (ja) | Ｓａｒｓ－ｃｏｖ－２又はその変異体の感染に抵抗するための医薬組成物及びその併用薬剤 | |
| WO2006009011A1 (ja) | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター | |
| WO2023236822A1 (zh) | H5n6禽流感广谱性疫苗的开发及其应用 | |
| HK40087930A (en) | Cytomegalovirus antigens and uses thereof | |
| WO2023047349A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| US20230331782A1 (en) | Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease | |
| KR20240052044A (ko) | 코로나바이러스과 바이러스에 의한 감염을 치료 또는 예방하기 위한 바이러스-유사 입자 | |
| CN116685347A (zh) | 编码嵌合冠状病毒刺突蛋白的重组载体及其用途 | |
| WO2007010399A2 (en) | Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections | |
| JP2023549787A (ja) | キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用 | |
| WO2023047348A1 (en) | Stabilized corona virus spike protein fusion proteins | |
| CN115894713A (zh) | 异源三聚体化融合蛋白、组合物及其应用 | |
| HK40086980A (zh) | 针对sars-cov-2的疫苗及其制备 | |
| Jaberolansar | Epitope-focused vaccines against respiratory syncytial virus |